Silenced expression of NFKBIA in lung adenocarcinoma patients with a never-smoking history

Masashi Furukawa, Junichi Sou, Hiromasa Yamamoto, Kouichi Ichimura, Kazuhiko Shien, Yuho Maki, Takayuki Muraoka, Norimitsu Tanaka, Tsuyoshi Ueno, Hiroaki Asano, Kazunori Tsukuda, Shinichi Toyooka, Shinichiro Miyoshi

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Nuclear factor of k-light polypeptide gene enhancer in B cells inhibitor a (NFKBIA), which is a tumor suppressor gene, was found to be silenced in lung adenocarcinomas. We examined NFKBIA expression, mutations in the EGFR and K-ras genes, and EML4-ALK fusion in 101 resected lung adenocarcinoma samples from never-smokers. NFKBIA expression was evaluated using immunohis-tochemistry. NFKBIA expression was negative in 16 of the 101 samples (15.8%). EGFR and K-ras mutations and EML4-ALK fusion were detected in 61 (60.5%), 1 (1.0%), and 2 (2.0%) of the 101 samples, respectively, in a completely mutually exclusive manner. Negative NFKBIA expression was observed significantly more frequently among the tumors with none of the three genetic alterations compared to those with such alterations (p - 0.009). In addition, negative NFKBIA expression was significantly more frequent among the EGFR-wild type samples compared to the EGFR-mutant samples (p - 0.013). In conclusion, NFKBIA expression was silenced in adenocarcinomas without EGFR/ K-ras mutations or EML4-ALK fusion, suggesting that the silencing of NFKBIA may play an important role in the carcinogenesis of adenocarcinomas independent of EGFR/K-ras mutations or EML4-ALK fusion.

Original languageEnglish
Pages (from-to)19-24
Number of pages6
JournalActa Medica Okayama
Volume67
Issue number1
Publication statusPublished - 2013

Fingerprint

Fusion reactions
Smoking
History
Mutation
Genes
Tumors
Adenocarcinoma
ras Genes
Tumor Suppressor Genes
Carcinogenesis
B-Lymphocytes
Cells
Light
Peptides
Adenocarcinoma of lung
Neoplasms

Keywords

  • Adenocarcinoma
  • Epidermal growth factor receptor
  • Lung cancer
  • Never-smoker
  • Nuclear factor of κ-light polypeptide gene enhancer in B cells inhibitor α

ASJC Scopus subject areas

  • Medicine(all)
  • Biochemistry, Genetics and Molecular Biology(all)

Cite this

Furukawa, M., Sou, J., Yamamoto, H., Ichimura, K., Shien, K., Maki, Y., ... Miyoshi, S. (2013). Silenced expression of NFKBIA in lung adenocarcinoma patients with a never-smoking history. Acta Medica Okayama, 67(1), 19-24.

Silenced expression of NFKBIA in lung adenocarcinoma patients with a never-smoking history. / Furukawa, Masashi; Sou, Junichi; Yamamoto, Hiromasa; Ichimura, Kouichi; Shien, Kazuhiko; Maki, Yuho; Muraoka, Takayuki; Tanaka, Norimitsu; Ueno, Tsuyoshi; Asano, Hiroaki; Tsukuda, Kazunori; Toyooka, Shinichi; Miyoshi, Shinichiro.

In: Acta Medica Okayama, Vol. 67, No. 1, 2013, p. 19-24.

Research output: Contribution to journalArticle

Furukawa, M, Sou, J, Yamamoto, H, Ichimura, K, Shien, K, Maki, Y, Muraoka, T, Tanaka, N, Ueno, T, Asano, H, Tsukuda, K, Toyooka, S & Miyoshi, S 2013, 'Silenced expression of NFKBIA in lung adenocarcinoma patients with a never-smoking history', Acta Medica Okayama, vol. 67, no. 1, pp. 19-24.
Furukawa, Masashi ; Sou, Junichi ; Yamamoto, Hiromasa ; Ichimura, Kouichi ; Shien, Kazuhiko ; Maki, Yuho ; Muraoka, Takayuki ; Tanaka, Norimitsu ; Ueno, Tsuyoshi ; Asano, Hiroaki ; Tsukuda, Kazunori ; Toyooka, Shinichi ; Miyoshi, Shinichiro. / Silenced expression of NFKBIA in lung adenocarcinoma patients with a never-smoking history. In: Acta Medica Okayama. 2013 ; Vol. 67, No. 1. pp. 19-24.
@article{b8c522a0ce9442b5868a833947240179,
title = "Silenced expression of NFKBIA in lung adenocarcinoma patients with a never-smoking history",
abstract = "Nuclear factor of k-light polypeptide gene enhancer in B cells inhibitor a (NFKBIA), which is a tumor suppressor gene, was found to be silenced in lung adenocarcinomas. We examined NFKBIA expression, mutations in the EGFR and K-ras genes, and EML4-ALK fusion in 101 resected lung adenocarcinoma samples from never-smokers. NFKBIA expression was evaluated using immunohis-tochemistry. NFKBIA expression was negative in 16 of the 101 samples (15.8{\%}). EGFR and K-ras mutations and EML4-ALK fusion were detected in 61 (60.5{\%}), 1 (1.0{\%}), and 2 (2.0{\%}) of the 101 samples, respectively, in a completely mutually exclusive manner. Negative NFKBIA expression was observed significantly more frequently among the tumors with none of the three genetic alterations compared to those with such alterations (p - 0.009). In addition, negative NFKBIA expression was significantly more frequent among the EGFR-wild type samples compared to the EGFR-mutant samples (p - 0.013). In conclusion, NFKBIA expression was silenced in adenocarcinomas without EGFR/ K-ras mutations or EML4-ALK fusion, suggesting that the silencing of NFKBIA may play an important role in the carcinogenesis of adenocarcinomas independent of EGFR/K-ras mutations or EML4-ALK fusion.",
keywords = "Adenocarcinoma, Epidermal growth factor receptor, Lung cancer, Never-smoker, Nuclear factor of κ-light polypeptide gene enhancer in B cells inhibitor α",
author = "Masashi Furukawa and Junichi Sou and Hiromasa Yamamoto and Kouichi Ichimura and Kazuhiko Shien and Yuho Maki and Takayuki Muraoka and Norimitsu Tanaka and Tsuyoshi Ueno and Hiroaki Asano and Kazunori Tsukuda and Shinichi Toyooka and Shinichiro Miyoshi",
year = "2013",
language = "English",
volume = "67",
pages = "19--24",
journal = "Acta Medica Okayama",
issn = "0386-300X",
publisher = "Okayama University",
number = "1",

}

TY - JOUR

T1 - Silenced expression of NFKBIA in lung adenocarcinoma patients with a never-smoking history

AU - Furukawa, Masashi

AU - Sou, Junichi

AU - Yamamoto, Hiromasa

AU - Ichimura, Kouichi

AU - Shien, Kazuhiko

AU - Maki, Yuho

AU - Muraoka, Takayuki

AU - Tanaka, Norimitsu

AU - Ueno, Tsuyoshi

AU - Asano, Hiroaki

AU - Tsukuda, Kazunori

AU - Toyooka, Shinichi

AU - Miyoshi, Shinichiro

PY - 2013

Y1 - 2013

N2 - Nuclear factor of k-light polypeptide gene enhancer in B cells inhibitor a (NFKBIA), which is a tumor suppressor gene, was found to be silenced in lung adenocarcinomas. We examined NFKBIA expression, mutations in the EGFR and K-ras genes, and EML4-ALK fusion in 101 resected lung adenocarcinoma samples from never-smokers. NFKBIA expression was evaluated using immunohis-tochemistry. NFKBIA expression was negative in 16 of the 101 samples (15.8%). EGFR and K-ras mutations and EML4-ALK fusion were detected in 61 (60.5%), 1 (1.0%), and 2 (2.0%) of the 101 samples, respectively, in a completely mutually exclusive manner. Negative NFKBIA expression was observed significantly more frequently among the tumors with none of the three genetic alterations compared to those with such alterations (p - 0.009). In addition, negative NFKBIA expression was significantly more frequent among the EGFR-wild type samples compared to the EGFR-mutant samples (p - 0.013). In conclusion, NFKBIA expression was silenced in adenocarcinomas without EGFR/ K-ras mutations or EML4-ALK fusion, suggesting that the silencing of NFKBIA may play an important role in the carcinogenesis of adenocarcinomas independent of EGFR/K-ras mutations or EML4-ALK fusion.

AB - Nuclear factor of k-light polypeptide gene enhancer in B cells inhibitor a (NFKBIA), which is a tumor suppressor gene, was found to be silenced in lung adenocarcinomas. We examined NFKBIA expression, mutations in the EGFR and K-ras genes, and EML4-ALK fusion in 101 resected lung adenocarcinoma samples from never-smokers. NFKBIA expression was evaluated using immunohis-tochemistry. NFKBIA expression was negative in 16 of the 101 samples (15.8%). EGFR and K-ras mutations and EML4-ALK fusion were detected in 61 (60.5%), 1 (1.0%), and 2 (2.0%) of the 101 samples, respectively, in a completely mutually exclusive manner. Negative NFKBIA expression was observed significantly more frequently among the tumors with none of the three genetic alterations compared to those with such alterations (p - 0.009). In addition, negative NFKBIA expression was significantly more frequent among the EGFR-wild type samples compared to the EGFR-mutant samples (p - 0.013). In conclusion, NFKBIA expression was silenced in adenocarcinomas without EGFR/ K-ras mutations or EML4-ALK fusion, suggesting that the silencing of NFKBIA may play an important role in the carcinogenesis of adenocarcinomas independent of EGFR/K-ras mutations or EML4-ALK fusion.

KW - Adenocarcinoma

KW - Epidermal growth factor receptor

KW - Lung cancer

KW - Never-smoker

KW - Nuclear factor of κ-light polypeptide gene enhancer in B cells inhibitor α

UR - http://www.scopus.com/inward/record.url?scp=84875856180&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84875856180&partnerID=8YFLogxK

M3 - Article

C2 - 23439505

AN - SCOPUS:84875856180

VL - 67

SP - 19

EP - 24

JO - Acta Medica Okayama

JF - Acta Medica Okayama

SN - 0386-300X

IS - 1

ER -